Abstract We set out to determine if our anti-sepsis drug candidate Rejuveinix (RJX) can effectively treat systemic inflammation in a mouse model of sepsis when used at a dose level that is &gt;10-times lower than its maximum tolerated dose (MTD) for human subjects. Our findings obtained in the LPS-GalN mouse model of fatal sepsis provide experimental evidence that RJX exhibits potent single-agent anti-inflammatory activity and reverses very severe inflammatory lung injury when used therapeutically, thereby significantly improving the survival outcome. These findings demonstrate the clinical impact potential of RJX for the treatment of severe sepsis.

Rejuveinix Reverses Severe Inflammatory Lung Damage in a Mouse Model of Fatal Sepsis